"Viridian Therapeutics sees stock soar after Phase III TED success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been ...

Viridian Therapeutics’s stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease (TED). The THRIVE-2 ...